.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,050,335

« Back to Dashboard

Claims for Patent: 9,050,335

Title:Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
Abstract: The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subjects body faster than it is being absorbed.
Inventor(s): Devarakonda; Krishna (St. Louis, MO), Giuliani; Michael J. (Creve Coeur, MO), Gupta; Vishal K. (Hillsborough, NJ), Heasley; Ralph A. (Webster Groves, MO), Shelby; Susan (Creve Coeur, MO)
Assignee: MALLINCKRODT LLC (Hazelwood, MO)
Application Number:13/473,586
Patent Claims: 1. A pharmaceutical composition for extended release of oxycodone and acetaminophen, comprising: at least one extended release portion comprising oxycodone or a pharmaceutically acceptable salt of oxycodone, acetaminophen, and an extended release component; wherein the total amount of acetaminophen in the composition is about 325 mg to about 650 mg, and the total amount of oxycodone or salt in the composition is about 7.5 mg to about 15 mg; wherein upon oral administration of the composition to a subject in a fasted state, the composition provides an AUC.sub.0-1.7h for acetaminophen of about 5 ngh/ml/mg to about 13 ngh/ml/mg; an AUC.sub.1.7-48h for acetaminophen of about 25 ngh/ml/mg to about 75 ngh/ml/mg; an AUC.sub.0-2.8h for oxycodone or salt of about 1 ngh/ml/mg to about 3 ngh/ml/mg; and AUC.sub.2.8-48h for oxycodone or salt of about 7.5 ngh/ml/mg to about 15 ngh/ml/mg.

2. The pharmaceutical composition of claim 1, wherein the AUC.sub.0-1.7h for acetaminophen is about 8.5 ngh/ml/mg to about 10 ngh/ml/mg.

3. The pharmaceutical composition of claim 1, wherein the AUC.sub.1.7-48h for acetaminophen is about 35 ngh/ml/mg to about 50 ngh/ml/mg.

4. The pharmaceutical composition of claim 1, wherein the AUC.sub.0-2.8h for oxycodone or salt is about 2.5 ngh/ml/mg to about 3.5 ngh/ml/mg.

5. The pharmaceutical composition of claim 1, wherein the AUC.sub.2.8-48h for oxycodone or salt is about 9.5 ngh/ml/mg to about 11.5 ngh/ml/mg.

6. The pharmaceutical composition of claim 1, wherein the composition comprises about 650 mg of acetaminophen and about 15 mg of oxycodone or salt.

7. The pharmaceutical composition of claim 1, wherein the composition comprises about 325 mg of acetaminophen and about 7.5 mg of oxycodone or salt.

8. The pharmaceutical composition of claim 7, wherein the composition is in the form of a tablet and a single dose comprises two tablets.

9. The pharmaceutical composition of claim 1, wherein the extended release component comprises at least one extended release polymer.

10. The pharmaceutical composition of claim 9, wherein the at least one extended release polymer is a polyethylene oxide.

11. The pharmaceutical composition of claim 10, wherein the molecular weight of the polyethylene oxide is from about 500,000 Daltons to about 10,000,000 Daltons.

12. The pharmaceutical composition of claim 1, wherein the composition further comprises at least one immediate release portion comprising oxycodone or a pharmaceutically acceptable salt of oxycodone, acetaminophen, or a combination thereof.

13. The pharmaceutical composition of claim 12, wherein the at least one immediate release portion comprises from about 20% to about 30% of the total amount of oxycodone or salt in the composition and from about 40% to about 60% of the total amount of acetaminophen in the composition; and the at least one extended release portion comprises the balance of each of the oxycodone or salt and the acetaminophen.

14. The pharmaceutical composition of claim 12, wherein the composition comprises (a) one immediate release portion comprising the oxycodone or salt and the acetaminophen, and (b) one extended release portion comprising the extended release polymer, the oxycodone or salt and the acetaminophen.

15. The pharmaceutical composition of claim 14, wherein the immediate release portion comprises, by weight of the immediate release portion, from about 70% to about 80% acetaminophen and from about 0.5% to about 1% of oxycodone or salt; and the extended release portion comprises, by weight of the extended release portion, from about 30% to about 50% of the extended release polymer, from about 20% to about 40% of acetaminophen, and from about 0.5% to about 2% of oxycodone or salt.

16. A pharmaceutical composition for extended release of oxycodone and acetaminophen, comprising: at least one extended release portion comprising oxycodone or a pharmaceutically acceptable salt of oxycodone, acetaminophen, and an extended release component; wherein the total amount of acetaminophen in the composition is about 325 mg to about 650 mg, and the total amount of oxycodone or salt in the composition is about 7.5 mg to about 15 mg; wherein upon oral administration of the composition to a subject in a fed state, the composition provides an AUC.sub.0-3.2h for acetaminophen of about 7 ngh/mL/mg to about 21 ngh/mL/mg; an AUC.sub.3.2-48h for acetaminophen of about 15 ngh/mL/mg to about 75 ngh/mL/mg; an AUC.sub.0-4.3h for oxycodone or salt of about 1.5 ngh/mL/mg to about 5.5 ngh/mL/mg; and AUC.sub.4.3-48h for oxycodone or salt of about 5.0 ngh/mL/mg to about 15 ngh/mL/mg.

17. The pharmaceutical composition of claim 16, wherein the AUC.sub.0-3.2h for acetaminophen is about 12 ngh/mL/mg to about 15 ngh/mL/mg.

18. The pharmaceutical composition of claim 16, wherein the AUC.sub.3.2-48h for acetaminophen is about 30 ngh/mL/mg to about 40 ngh/mL/mg.

19. The pharmaceutical composition of claim 16, wherein the AUC.sub.0-4.3h for oxycodone or salt is about 3.0 ngh/ml/mg to about 4.0 ngh/ml/mg.

20. The pharmaceutical composition of claim 16, wherein the AUC.sub.4.3-48h for oxycodone or salt is about 9.5 ngh/ml/mg to about 11.5 ngh/ml/mg.

21. The pharmaceutical composition of claim 16, wherein the composition comprises about 650 mg of acetaminophen and about 15 mg of oxycodone or salt.

22. The pharmaceutical composition of claim 16, wherein the composition comprises about 325 mg of acetaminophen and about 7.5 mg of oxycodone or salt.

23. The pharmaceutical composition of claim 22, wherein the composition is in the form of a tablet and a single dose comprises two tablets.

24. The pharmaceutical composition of claim 16, wherein the extended release component comprises at least one extended release polymer.

25. The pharmaceutical composition of claim 24, wherein the at least one extended release polymer is a polyethylene oxide.

26. The pharmaceutical composition of claim 25, wherein the molecular weight of the polyethylene oxide is from about 500,000 Daltons to about 10,000,000 Daltons.

27. The pharmaceutical composition of claim 16, wherein the composition further comprises at least one immediate release portion comprising oxycodone or a pharmaceutically acceptable salt of oxycodone, acetaminophen, or a combination thereof.

28. The pharmaceutical composition of claim 27, wherein the at least one immediate release portion comprises from about 20% to about 30% of the total amount of oxycodone or salt in the composition and from about 40% to about 60% of the total amount of acetaminophen in the composition; and the at least one extended release portion comprises the balance of each of the oxycodone or salt and the acetaminophen.

29. The pharmaceutical composition of claim 27, wherein the composition comprises (a) one immediate release portion comprising the oxycodone or salt and the acetaminophen, and (b) one extended release portion comprising the extended release polymer, the oxycodone or salt and the acetaminophen.

30. The pharmaceutical composition of claim 29, wherein the immediate release portion comprises, by weight of the immediate release portion, from about 70% to about 80% acetaminophen and from about 0.5% to about 1% of oxycodone or salt; and the extended release portion comprises, by weight of the extended release portion, from about 30% to about 50% of the extended release polymer, from about 20% to about 40% of acetaminophen, and from about 0.5% to about 2% of oxycodone or salt.

31. An extended release pharmaceutical composition, comprising: at least one extended release portion comprising oxycodone or a pharmaceutically acceptable salt of oxycodone, acetaminophen, and an extended release component; wherein the total amount of acetaminophen in the composition is about 325 mg to about 650 mg, and the total amount of oxycodone or salt in the composition is about 7.5 mg to about 15 mg; wherein when the composition is orally administered to a subject in need thereof, the subject attains therapeutic blood levels of both the oxycodone and the acetaminophen within about one hour after administration of the composition and maintains analgesia for about 12 hours after administration of the composition; and wherein upon placement of the composition in an in vitro dissolution test comprising USP Paddle Method at a paddle speed of about 100 rpm in 900 ml of 0.1N HCl using a USP type II apparatus at a constant temperature of 37.degree. C., the drug release profile substantially corresponds to the following: after 15 minutes, about 25% to about 35%, by weight, of the total amount of oxycodone or salt thereof in the composition is released and about 50% to about 55%, by weight, of the total amount of acetaminophen in the composition is released; after 1 hour, about 40% to about 50%, by weight, of the total amount of oxycodone or salt thereof in the composition is released and about 50% to about 65%, by weight, of the total amount of acetaminophen in the composition is released; after 2 hours, no more than about 65%, by weight, of the total amount of the oxycodone or salt is released and no more than about 75%, by weight, of the total amount of the acetaminophen is released; after 4 hours, from about 65% to about 85%, by weight, of the total amount of the oxycodone or salt is released and from about 70% to about 90%, by weight, of the total amount of the acetaminophen is released; after 8 hours, from about 85% to about 100%, by weight, of the total amount of the oxycodone or salt is released and from about 85% to about 100%, by weight, of the total amount of the acetaminophen is released; and after 12 hours, from about 95% to about 100%, by weight, of the total amount of the oxycodone or salt is released and from about 90% to about 100%, by weight, of the total amount of the acetaminophen is released.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc